SAN DIEGO, June 13, 2017 /PRNewswire/ -- Avelas Biosciences, Inc., a clinical stage oncology-focused company dedicated toimproving cancer patient care from diagnosis through treatment, today announced that Carmine N. Stengone, president and chief executive officer, will be a panel participant at the JMP Securities Life Sciences Conference,
About Avelas Biosciences
Avelas Biosciences is a San Diego-based biotechnology company focused on developing technologies that advance a new standard-of-care for cancer surgery and therapeutic intervention. The company's lead candidate, AVB-620, has completed a Phase 1b clinical trial assessing safety, pharmacokinetics and fluorescence properties using tissue image analysis. The initiation of a Phase 2 clinical trial for AVB-620 in breast cancer is expected in the first half of 2017. In addition, the company is advancing a therapeutic program, which utilizes the same technology platform. Avelas was founded by Avalon Ventures on technology from Roger Y. Tsien, Ph.D., co-winner of the 2008 Nobel Prize in chemistry. For additional information, please visit www.avelasbio.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/avelas-biosciences-to-participate-in-jmp-securities-life-sciences-conference-300473283.html
SOURCE Avelas Biosciences, Inc.
Subscribe to our Free Newsletters!
Necrotizing fasciitis is a rare life threatening bacterial infection of the tissue below the skin ...
Menstruation or period is the discharge of blood and mucus called menses from the uterus via the ...
Chronic dieting is associated with eating disorders that mainly include unhealthy eating practices ...View All